12-Hydroxydodecanoic acid

Catalog No.S3089 Synonyms: G12

For research use only.

12-Hydroxydodecanoic acid (G12) is an active endogenous metabolite.

12-Hydroxydodecanoic acid Chemical Structure

CAS No. 505-95-3

Purity & Quality Control

Related Other Products

Biological Activity


12-Hydroxydodecanoic acid (G12) is an active endogenous metabolite.

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 216.32


CAS No. 505-95-3
Storage 3 years -20°C powder
2 years -80°C in solvent

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05400577 Not yet recruiting Drug: Sotorasib 960 mg oral daily dose for 4 weeks (28 days) Non-Small Cell Lung Cancer Fox Chase Cancer Center July 1 2022 Phase 2
NCT05382559 Recruiting Drug: ASP3082 Solid Tumor Astellas Pharma Inc June 8 2022 Phase 1
NCT05178888 Recruiting Drug: MRTX849|Drug: Palbociclib Advanced Solid Tumor Mirati Therapeutics Inc. February 1 2022 Phase 1
NCT04975256 Active not recruiting Drug: MRTX849|Drug: BI 1701963 Advanced Cancer|Metastatic Cancer|Malignant Neoplasm of Colon|Malignant Neoplasm of Lung|Malignant Neoplastic Disease Mirati Therapeutics Inc.|Boehringer Ingelheim August 12 2021 Phase 1
NCT05383898 Recruiting Drug: D-1553 NSCLC InventisBio Co. Ltd March 16 2021 Phase 1|Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy 12-Hydroxydodecanoic acid | 12-Hydroxydodecanoic acid supplier | purchase 12-Hydroxydodecanoic acid | 12-Hydroxydodecanoic acid cost | 12-Hydroxydodecanoic acid manufacturer | order 12-Hydroxydodecanoic acid | 12-Hydroxydodecanoic acid distributor